Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma

NCT00033462 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00033462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00033462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2002
Completion date
Not reported
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult primary cholangiocellular carcinoma, adult primary hepatocellular carcinoma, advanced adult primary liver cancer, cholangiocarcinoma of the extrahepatic bile duct, cholangiocarcinoma of the gallbladder, localized unresectable adult primary liver cancer, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, recurrent gallbladder cancer, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer